24/01/2018 01:29:30

Adamas Announces Pricing of Public Offering of Common Stock

Related content
08 Aug - 
Adamas Announces New Employment Inducement Grant
02 Aug - 
Adamas Reports Second Quarter 2018 Financial Results
01 Aug - 
Adamas Pharmaceuticals Launches “Dyskinesia Is A Jerk™,..

EMERYVILLE, Calif., Jan. 23, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the pricing of its underwritten public offering of 3,000,000 shares of its common stock at a price to the public of $41.50 per share. The aggregate gross proceeds from this offering are expected to be $124,500,000, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Adamas. Adamas also granted the underwriters a 30-day option to acquire up to an additional 450,000 shares from Adamas. The offering is expected to close on January 26, 2018, subject to customary closing conditions.

BofA Merrill Lynch, Leerink Partners and Evercore ISI are acting as book-running managers for the proposed offering.

A shelf registration statement relating to the shares was filed with the Securities and Exchange Commission on November 3, 2016, and became effective on November 21, 2016. The offering will be made only by means of a prospectus supplement. When available, copies of the prospectus supplement and accompanying prospectus relating to the public offering may be obtained by contacting BofA Merrill Lynch,  NC1-004-03, 200 North College Street, 3rd floor, Charlotte NC 28255-0001, Attn: Prospectus Department, email: dg.prospectus_requests@baml.com; Leerink Partners, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at (800) 808-7525 ext. 6132 or by email at Syndicate@Leerink.com; or Evercore ISI, Attention: Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York, NY 10055, or by telephone at (888) 474-0200 or by email at ecm.prospectus@evercore.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Adamas Pharmaceuticals, Inc.

Adamas is a pharmaceutical company committed to developing and commercializing products and product candidates for the treatment of chronic neurological disorders.

Forward-Looking Statements

This announcement contains forward-looking statements, including statements relating to Adamas’ expectations regarding the completion of the proposed public offering. These statements are subject to significant risks and uncertainties, actual results could differ materially from those projected and Adamas cautions investors not to place undue reliance on the forward-looking statements contained in this release. These risks and uncertainties include, without limitation, risks and uncertainties related to market conditions and satisfaction of customary closing conditions related to the public offering. There can be no assurance that Adamas will be able to complete the public offering on the anticipated terms, or at all. Risks and uncertainties relating to Adamas and its business can be found in the “Risk Factors” section of Adamas’ Form 8-K, filed with the SEC on January 22, 2018, and in the preliminary prospectus supplement related to the offering filed with the SEC on January 22, 2018. Adamas undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in Adamas’ expectations.      

For questions, please contact:

Ashleigh Barreto

Director, Corporate Communications & Investor Relations

Adamas Pharmaceuticals, Inc.

510-450-3567

Primary Logo

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

Related news
21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Assure Holdings Reports First Quarter 2018 Financial Results
2
Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Zoe’s Kitchen, Inc. (ZOES) on Behalf of Stockholders and Encourages Investors to Contact the Firm
3
Coherus BioSciences Announces New Employment Inducement Grants
4
Red Eagle Mining Reports Q2 2018 Financial Results
5
FARMLAND PARTNERS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Farmland Partners Inc. – FPI, FPI-PB

Related stock quotes

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2018   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
18 August 2018 20:51:14
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20180816.1 - EUROWEB1 - 2018-08-18 21:51:14 - 2018-08-18 20:51:14 - 1000 - Website: OKAY